73 related articles for article (PubMed ID: 19561650)
1. Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML.
Garland P; Dazzi F; Marin D
Bone Marrow Transplant; 2010 Feb; 45(2):395-6. PubMed ID: 19561650
[No Abstract] [Full Text] [Related]
2. Coexistence of translocation(1,19) and the Philadelphia chromosome in a child's first presentation of chronic myeloid leukemia in blast crisis treated with dasatinib.
Eckardt MA; Chang VY; Rao NP; Federman N
Pediatr Hematol Oncol; 2011 Nov; 28(8):669-75. PubMed ID: 22023462
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Breccia M; Capria S; Iori AP; Foà R; Alimena G; Meloni G
Acta Haematol; 2010; 124(3):150-2. PubMed ID: 20938169
[No Abstract] [Full Text] [Related]
5. Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.
Raanani P
Acta Haematol; 2013; 130(2):108-10. PubMed ID: 23548690
[No Abstract] [Full Text] [Related]
6. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
[No Abstract] [Full Text] [Related]
7. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?
Breccia M; Cannella L; Stefanizzi C; Carotti A; Santopietro M; Alimena G
Bone Marrow Transplant; 2009 Sep; 44(5):331-2. PubMed ID: 19219075
[No Abstract] [Full Text] [Related]
8. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.
Raiola AM; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Bregante S; di Grazia C; Dominietto A; Soracco M; Romagnani C; Vassallo F; Casini M; Bruno B; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 2003 Apr; 31(8):687-93. PubMed ID: 12692609
[TBL] [Abstract][Full Text] [Related]
9. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion.
Porter D; Levine JE
Semin Hematol; 2006 Jan; 43(1):53-61. PubMed ID: 16412789
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
[TBL] [Abstract][Full Text] [Related]
12. Splenectomy status of the patient may have impact on response to donor lymphocyte infusions.
Uckan-Cetinkaya D; Unal S; Cetin M; Sarikabadayi U; Aktaş D; Koç Y
Leukemia; 2007 Sep; 21(9):2049-50; author reply 2050-1. PubMed ID: 17554372
[No Abstract] [Full Text] [Related]
13. Management of Bcr-Abl-positive leukemias with dasatinib.
Hochhaus A
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
[TBL] [Abstract][Full Text] [Related]
14. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
16. Basophilic blast phase of chronic myelogenous leukemia.
Babiker HM; Proytcheva M
Blood; 2014 Oct; 124(15):2464. PubMed ID: 25436261
[No Abstract] [Full Text] [Related]
17. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
Martinelli G; Montefusco V; Testoni N; Amabile M; Saglio G; Ottaviani E; Terragna C; Bonifazi F; Rosti G; Bandini G; Tura S
Haematologica; 2000 Jun; 85(6):653-8. PubMed ID: 10870124
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
19. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Valent JN; Schiffer CA
Leuk Res; 2011 Jan; 35(1):e1-3. PubMed ID: 20888043
[No Abstract] [Full Text] [Related]
[Next] [New Search]
